Latest Headlines
-
Fujifilm Appoints Lars Petersen As President & CEO Of FUJIFILM Diosynth Biotechnologies, Leading Global Bio CDMO
6/29/2023
Petersen succeeds Martin Meeson who has served as FUJIFILM Diosynth Biotechnologies president and CEO since 2020.
-
Project Farma And Precision For Medicine Acquire Baseline Controls
6/27/2023
Precision for Medicine, the first global biomarker-driven clinical research and development organization, today announced that it has acquired Baseline Controls, a Raleigh, North Carolina-based company that provides dedicated engineers with specialized expertise in project feasibility, execution planning, and baseline performance management. Baseline Control’s expertise will become part of Project Farma, Precision for Medicine’s existing biomanufacturing strategy and execution group, expanding the scope of its manufacturing solutions for life science companies and driving greater speed and efficiency in bringing new drugs to market.
-
NIIMBL Funding Helps To Accelerate Bringing Gene Therapies To Market
6/27/2023
New funding from NIIMBL was announced to develop a viral and exotoxin clearance platform for AAV manufacturing. The goal of this project is to establish new standards and advance gene therapies.
-
Precision NanoSystems And Aurora Vaccines Join Forces To Accelerate The Development Of Vaccine Candidate For Hepatitis C Virus
6/23/2023
Global leader in non-viral delivery of genomic medicines, Precision NanoSystems (PNI), entered into a strategic collaboration agreement with Aurora Vaccines to accelerate the development and manufacture of its Hepatitis C vaccine candidate. PNI will share its expertise in the development of the RNA payload platform and its proprietary lipid nanoparticle (LNP) platforms to help bring Aurora’s RNA-LNP vaccine candidate for the prevention of Hepatitis C virus (HCV) infection to a Phase I clinical trial.
-
Novotech Selected For Biotech CRO Leadership Award 2023
6/21/2023
Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities has been selected for the prestigious CRO Leadership Award 2023 for exceeding biotech customer expectations in the “Compatibility” category.
-
Prokidney Announces Plans For New Cell Therapy Manufacturing Facility In North Carolina
6/13/2023
ProKidney Corp. (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced its agreement to purchase a 210,000 square foot facility and approximately 22 acres of land in Greensboro, N.C., to support the Company’s future commercial manufacturing needs for REACT®, its proprietary REnal Autologous Cell Therapy, currently in Phase 3 development for the treatment of diabetic CKD.
-
Qosina And Carolina Components Partner To Promote FlowLinX Bioprocessing Components
6/8/2023
Qosina, a global supplier of OEM single-use components to the medical and biopharmaceutical industries, is happy to announce its partnership with Carolina Components Group, a leading supplier of primary and support production materials for the pharmaceutical and biotech manufacturing industries.
-
Presentations, Roundtable Discussions, And Interviews: ISCT Paris 2023
6/8/2023
As a CDMO specializing in cell therapy manufacturing, BioCentriq was eager to participate in this event focused on cell and gene therapy translation, which takes an integrative approach across all stakeholders to tackle key topics ranging from translational research and preclinical development through clinical trials, regulatory approvals, commercialization, and the ultimate goal of patient access.
-
BioCentriq Hosts Cohort From Bpeace Pharma Maximizer Program
6/7/2023
BioCentriq had the great pleasure of hosting ten leaders from five different Salvadoran businesses who are participants in Bpeace’s Pharma Maximizer program.
-
BioCentriq, Kytopen Expand Partnership To Optimize CGT Manufacturing
6/6/2023
Learn how the extended partnership will expand therapeutic developers’ access to a leading non-viral cell engineering method by combining BioCentriq’s process development expertise with Kytopen’s Flowfect Discover™ platform.